慢性乙型肝炎患者抗病毒治疗过程中的免疫应答特点

王卫彬; 李咏茵; 侯金林

doi:10.3969/j.issn.1001-5256.2016.10.007

慢性乙型肝炎患者抗病毒治疗过程中的免疫应答特点

DOI: 10.3969/j.issn.1001-5256.2016.10.007

器官衰竭防治国家重点实验室，广东省病毒性肝炎研究重点实验室，南方医科大学南方医院感染内科暨肝病中心

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2299
- HTML全文浏览量: 33
- PDF下载量: 556
- 被引次数: 0
出版历程
- 出版日期: 2016-10-20

Features of immune response during antiviral therapy in patients with chronic hepatitis B

State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University

摘要

摘要:
宿主的免疫应答是一把双刃剑,参与慢性HBV感染的肝损伤和病毒控制,核苷和核苷酸类药物及干扰素抗病毒治疗可以通过调节宿主免疫应答影响预后。简要论述了宿主免疫应答在慢性HBV感染中的作用及其在抗病毒治疗过程中的特点,指出宿主免疫功能重建在持久HBV感染控制中的重要性。
- 肝炎,乙型,慢性 /
- 抗病毒药 /
- 免疫
Abstract:
Host immune response is a double-edged sword and participates in liver injury and viral control in patients with HBV infection.Antiviral therapy with nucleos( t) ide analogues and interferon may improve prognosis through regulating host immune response. This article describes the role of host immune response in chronic HBV infection and its features during antiviral therapy and emphasizes the importance of host immune reconstruction in sustained control of HBV infection.
- hepatitis B /
- chronic /
- antiviral agents

HTML全文

参考文献(47)

[1]MOMENI M,ZAINODINI N,BIDAKI R,et al.Decreased expression of toll like receptor signaling molecules in chronic HBV infected patients[J].Hum Immunol,2014,75(1):15-19.

[2]LIU S,PENG N,XIE J,et al.Human hepatitis B virus surface and e antigens inhibit major vault protein signaling in interferon induction pathways[J].J Hepatol,2015,62(5):1015-1023.

[3]FLETCHER SP,CHIN DJ,JI Y,et al.Transcriptomic analysis of the woodchuck model of chronic hepatitis B[J].Hepatology,2012,56(3):820-830.

[4]WIELAND S,THIMME R,PURCELL RH,et al.Genomic analysis of the host response to hepatitis B virus infection[J].Proc Natl Acad Sci U S A,2004,101(17):6669-6674.

[5]DICKSON I.Viral hepatitis:a lack of hepatocyte STING favours HBV infection[J].Nat Rev Gastroenterol Hepatol,2016,13(8):438.

[6]CHRISTEN V,DUONG F,BERNSMEIER C,et al.Inhibition of alpha interferon signaling by hepatitis B virus[J].J Virol,2007,81(1):159-165.

[7]BERTOLETTI A,FERRARI C.Innate and adaptive immune responses in chronic hepatitis B virus infections:towards restoration of immune control of viral infection[J].Gut,2012,61(12):1754-1764.

[8]DECORSIERE A,MUELLER H,van BREUGEL PC,et al.Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor[J].Nature,2016,531(7594):386-389.

[9]MARTINET J,DUFEU-DUCHESNE T,BRUDER CJ,et al.Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection[J].Gastroenterology,2012,143(6):1586-1596.

[10]GHOSH S,NANDI M,PAL S,et al.Natural killer cells contribute to hepatic injury and help in viral persistence during progression of hepatitis B e-antigen-negative chronic hepatitis B virus infection[J].Clin Microbiol Infect,2016.[Epub ahead of print]

[11]PALLETT LJ,GILL US,QUAGLIA A,et al.Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells[J].Nat Med,2015,21(6):591-600.

[12]XU X,SHANG Q,CHEN X,et al.Reversal of B-cell hyperactivation and functional impairment is associated with HBs Ag seroconversion in chronic hepatitis B patients[J].Cell Mol Immunol,2015,12(3):309-316.

[13]DAS A,ELLIS G,PALLANT C,et al.IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection[J].J Immunol,2012,189(8):3925-3935.

[14]BERTOLETTI A,MAINI MK,FERRARI C.The host-pathogen interaction during HBV infection:immunological controversies[J].Antivir Ther,2010,15(Suppl 3):15-24.

[15]BENGSCH B,MARTIN B,THIMME R.Restoration of HBV-specific CD8+T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation[J].J Hepatol,2014,61(6):1212-1219.

[16]BONI C,LAMPERTICO P,TALAMONA L,et al.Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B[J].Hepatology,2015,62(6):1697-1709.

[17]KENNEDY PT,SANDALOVA E,JO J,et al.Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B[J].Gastroenterology,2012,143(3):637-645.

[18]SETO WK,CHAN TS,HWANG YY,et al.Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma:a prospective study[J].J Clin Oncol,2014,32(33):3736-3743.

[19]YAPALI S,TALAAT N,LOK AS.Management of hepatitis B:our practice and how it relates to the guidelines[J].Clin Gastroenterol Hepatol,2014,12(1):16-26.

[20]HADZIYANNIS SJ,SEVASTIANOS V,RAPTI I,et al.Sustained responses and loss of HBs Ag in HBe Ag-negative patients with chronic hepatitis B who stop long-term treatment with adefovir[J].Gastroenterology,2012,143(3):629-636.

[21]MELCHJORSEN J,RISOR MW,SOGAARD OS,et al.Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells[J].J Acquir Immune Defic Syndr,2011,57(4):265-275.

[22]WU ZG,YAN WM,GUO W,et al.Telbivudine preserves Thelper 1 cytokine production and downregulates programmed death ligand 1 in a mouse model of viral hepatitis[J].J Viral Hepat,2010,17(Suppl 1):24-33.

[23]TAN AT,HOANG LT,CHIN D,et al.Reduction of HBV replication prolongs the early immunological response to IFNαtherapy[J].J Hepatol,2014,60(1):54-61.

[24]van der MOLEN RG,SPRENGERS D,BIESTA PJ,et al.Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV[J].Hepatology,2006,44(4):907-914.

[25]TJWA ET,van OORD GW,HEGMANS JP,et al.Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B[J].J Hepatol,2011,54(2):209-218.

[26]PEPPA D,MICCO L,JAVAID A,et al.Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection[J].PLo S Pathog,2010,6(12):e1001227.

[27]TJWA ET,ZOUTENDIJK R,van OORD GW,et al.Similar frequencies,phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate(TDF)[J].Antiviral Res,2016,132:70-75.

[28]CHEN Y,LI X,YE B,et al.Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B[J].Antiviral Res,2011,91(1):23-31.

[29]BONI C,LACCABUE D,LAMPERTICO P,et al.Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues[J].Gastroenterology,2012,143(4):963-973.

[30]EVANS A,RIVA A,COOKSLEY H,et al.Programmed death 1expression during antiviral treatment of chronic hepatitis B:Impact of hepatitis B e-antigen seroconversion[J].Hepatology,2008,48(3):759-769.

[31]LI Y,MA S,TANG L,et al.Circulating chemokine(C-X-C Motif)receptor 5(+)CD4(+)T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection[J].Hepatology,2013,58(4):1277-1286.

[32]BONI C,PENNA A,BERTOLETTI A,et al.Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B[J].J Hepatol,2003,39(4):595-605.

[33]BONI C,PENNA A,OGG GS,et al.Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B:new perspectives for immune therapy[J].Hepatology,2001,33(4):963-971.

[34]PEPPA D,GILL US,REYNOLDS G,et al.Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion[J].J Exp Med,2013,210(1):99-114.

[35]KONDO Y,UENO Y,KOBAYASHI K,et al.Hepatitis B virus replication could enhance regulatory T cell activity by producing soluble heat shock protein 60 from hepatocytes[J].J Infect Dis,2010,202(2):202-213.

[36]ALLWEISS L,VOLZ T,LUTGEHETMANN M,et al.Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration[J].J Hepatol,2014,60(3):500-507.

[37]SADLER AJ,WILLIAMS BR.Interferon-inducible antiviral effectors[J].Nat Rev Immunol,2008,8(7):559-568.

[38]XU C,GUO H,PAN XB,et al.Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus[J].J Virol,2010,84(18):9332-9340.

[39]BELLONI L,ALLWEISS L,GUERRIERI F,et al.IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear ccc DNA minichromosome[J].J Clin Invest,2012,122(2):529-537.

[40]LUCIFORA J,XIA Y,REISINGER F,et al.Specific and nonhepatotoxic degradation of nuclear hepatitis B virus ccc DNA[J].Science,2014,343(6176):1221-1228.

[41]MICCO L,PEPPA D,LOGGI E,et al.Differential boosting of innate and adaptive antiviral responses during pegylated-interferonalpha therapy of chronic hepatitis B[J].J Hepatol,2013,58(2):225-233.

[42]REHERMANN B,LAU D,HOOFNAGLE JH,et al.Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection[J].J Clin Invest,1996,97(7):1655-1665.

[43]MARCELLIN P,AHN SH,MA X,et al.Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B[J].Gastroenterology,2016,150(1):134-144.

[44]XIE Q,ZHOU H,BAI X,et al.A randomized,open-label clinical study of combined pegylated interferon alfa-2a(40KD)and entecavir treatment for hepatitis B“e”antigen-positive chronic hepatitis B[J].Clin Infect Dis,2014,59(12):1714-1723.

[45]CAREY I,D'ANTIGA L,BANSAL S,et al.Immune and viral profile from tolerance to hepatitis B surface antigen clearance:a longitudinal study of vertically hepatitis B virus-infected children on combined therapy[J].J Virol,2011,85(5):2416-2428.

[46]de NIET A,STELMA F,JANSEN L,et al.Restoration of T cell function in chronic hepatitis B patients upon treatment with interferon based combination therapy[J].J Hepatol,2016,64(3):539-546.

[47]BRUDER CJ,DUFEU-DUCHESNE T,LEROY V,et al.Pegylated interferon alpha-2a triggers NK-cell functionality and specific T-cell responses in patients with chronic HBV infection without HBs Ag seroconversion[J].PLo S One,2016,11(6):e158297.

施引文献

资源附件(0)

访问统计